to provide a pharmaceutical composition comprising sustained-release lipid initial formulation of cationic pharmacologically active substance and this. present invention includes a) a liquid crystal forming agent, b) a neutral phospholipid and (neutral phospholipid), c) a liquid crystal curing agent, d) an anionic fixing agent (anionic anchoring agent), and, to provide a sustained-release lipid initial formulation to form a liquid crystal on the present and the aqueous fluid as lipid liquid phase in the absence of aqueous fluid (pre-concentrate). Slow release lipid initial formulations of the present invention exhibit a function and effect that it is possible to enhance the sustained release of cationic pharmacologically active substances anionic fixing agent and through ionic bonds between the cationic pharmacologically active substance .FIELD 3カチオン性薬理学的活性物質の徐放性脂質初期製剤およびこれを含む薬剤学的組成物を提供すること。 本発明は、a)液晶形成剤と、b)中性リン脂質(neutral phospholipid)と、c)液晶硬化剤と、d)アニオン性定着剤(anionic anchoring agent)と、を含み、水性流体の不在下で脂質液相として存在し且つ水性流体上で液晶を形成する徐放性脂質初期製剤(pre-concentrate)を提供する。本発明の徐放性脂質初期製剤は、アニオン性定着剤およびカチオン性薬理学的活性物質間のイオン結合を通じてカチオン性薬理学的活性物質の徐放性を強化させることができるという作用効果を示す。【選択図】図3
